{
    "data": [
        {
            "id": "4557908",
            "title": "uniQure falls after FDA commissioner’s comments on rare disease therapy",
            "description": "<html><body><p data-eci=\"true\">uniQure (<span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/QURE\" title=\"uniQure N.V.\">QURE</a></span></span>) shares fell ~28% on Thursday after FDA Commissioner Marty Makary, in a potential reference to Danish biotech’s gene therapy AMT-130, suggested his agency will not approve drugs that are associated with patient morbidity.</p>\n<p>His comments come at a time when uniQure (<a href=\"https://seekingalpha.com/symbol/QURE\" title=\"uniQure N.V.\">QURE</a>) is seeking FDA accelerated approval for AMT-130, which is designed to treat a rare genetically driven neurodegenerative disorder <a href=\"https://seekingalpha.com/news/4538012-uniqure-gains-as-fda-sets-up-meeting-on-gene-therapy\" rel=\"noopener\" target=\"_blank\">called Huntington’s disease.</a></p>\n<p>During an interview with CNBC on rare-disease drug approvals on Thursday, Makary said, \"I think there has been a bit of an effort to find a boogeyman to account for certain products that were not approved.”</p>\n<p>“For example, there was a product where the researchers drilled a burr hole, literally a hole in people's skulls, to interact inject intrathecally into the ventricle\" as part of a randomized controlled trial.</p>\n<p>AMT-130 is administered directly into patients’ brain tissue through a neurosurgical procedure. “At the end of the randomization period, it's found no benefit, and yet, this is one of the drugs that we were pressured to approve,” Makary added.</p>\n<p>“I have a lot of sympathy for those patients. There's <a href=\"https://x.com/adamfeuerstein/status/2027027966945829196?s=20\" rel=\"noopener\" target=\"_blank\">nothing out</a> there to offer them, but we're not going to go ahead and approve something like that that has morbidity associated with it,” he said.</p>\n<p><span data-preserver-spaces=\"true\">However, Leerink Partners reaffirmed its Outperform rating on uniQure (<a href=\"https://seekingalpha.com/symbol/QURE\" title=\"uniQure N.V.\">QURE</a>), arguing that the drug Makary referred to could be </span><span data-preserver-spaces=\"true\">Regenxbio’s</span><span data-preserver-spaces=\"true\"> (<a href=\"https://seekingalpha.com/symbol/RGNX\" title=\"REGENXBIO Inc.\">RGNX</a>) RGX-121 and not AMT-130.</span></p>\n<p><span data-preserver-spaces=\"true\">A gene therapy targeting rare neurodegenerative diseases known as Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis type I (MPS I), RGX-121, is delivered intrathecally into a ventricle using burr holes, analyst Joseph Schwartz argued. </span></p>\n<p><span data-preserver-spaces=\"true\">He added that it is not the </span><span data-preserver-spaces=\"true\">FDA's</span><span data-preserver-spaces=\"true\"> policy to comment on a drug under its review. Instead,</span><span data-preserver-spaces=\"true\"> “</span><span data-preserver-spaces=\"true\">this suggests this was about a drug that had been officially reviewed and rejected,</span><span data-preserver-spaces=\"true\">” </span><span data-preserver-spaces=\"true\">the analyst wrote, referring to RGX-121, for which the FDA issued a complete response </span><a href=\"https://seekingalpha.com/news/4549257-regenxbio-stock-drops-on-fda-setback-for-rgx-121-gene-therapy\" rel=\"noopener\" target=\"_blank\"><span data-preserver-spaces=\"true\">letter earlier this month</span></a><span data-preserver-spaces=\"true\">.</span></p>\n<p><em><span data-preserver-spaces=\"true\">Update 11.37 AM ET: Adds comments from Leerink Partners</span></em></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557908-uniqure-falls-fda-commissioners-comments",
            "pub_date": "2026-02-27 00:40:50",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557948",
            "title": "Cascades Non-GAAP EPS of $0.40, revenue of $4.77M",
            "description": "<html><body><ul>\n<li>Cascades <a href=\"https://seekingalpha.com/pr/20414789-cascades-reports-results-for-the-fourth-quarter-and-full-year-2025\">press release</a>  (CADNF): Q4  Non-GAAP EPS of C$0.40.</li>\n<li>Revenue of C$4.77M.</li>\n</ul>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557948-cascades-non-gaap-eps-of-0_40-revenue-of-4_77m",
            "pub_date": "2026-02-27 00:40:50",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557945",
            "title": "Akebia outlines 2026 pipeline expansion and expects Vafseo data catalysts in $1B dialysis market",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: Akebia Therapeutics (AKBA) Q4 2025  </p>\n<h3>Management View</h3>\n<ul>\n<li>CEO John Butler emphasized that \"2025 was an important year for Akebia, marked by the commercial launch of Vafseo\" and highlighted total net product revenue of $227 million for the year, with Vafseo and Auryxia as key contributors. Butler noted, \"the body of evidence is growing that supports the potential for Vafseo to become standard of care in what is a $1 billion U.S. market opportunity after the TDAPA period ends when we expect Vafseo will be priced roughly in parity with ESA pricing.\"</li>\n<li>Butler discussed the impact of new clinical data, stating, \"At the ASN meeting in November, we presented a post-hoc hierarchical composite endpoint analysis...patients treated with Vafseo experienced a lower risk of dying or being hospitalized than patients treated with the ESA comparator.\"</li>\n<li>The CEO announced a cost comparison analysis to be presented at the ADC, showing Vafseo \"demonstrated a 7.7% lower annual hospitalization rate, 16% reduction in hospitalization days and...approximately 15% lower Medicare hospitalization costs for patients treated with Vafseo versus darbepoetin.\"</li>\n<li>Butler introduced the company’s rare kidney disease pipeline, noting, \"Strategically, this initiative is a natural extension for us as it leverages our expertise in kidney disease drug development.\" Plans include an R&amp;D Day on April 2 to discuss mid-stage assets such as praliciguat and AKB-097, with a Phase II trial for praliciguat and a Phase II basket trial for AKB-097 expected to initiate in the second half of 2026.</li>\n<li>SVP &amp; Chief Commercial Officer Nicholas Grund reported, \"During the quarter, approximately 800 prescribers wrote a prescription for Vafseo...128 of those were new prescribers.\" Grund highlighted expanding access, improved adherence, and momentum in 2026, with \"first refill adherence with approximately 87% among the now larger subset of patients on an observed dosing regimen.\"</li>\n<li>CFO Erik Ostrowski stated, \"Total revenues were $57.6 million in Q4 '25 compared to $46.5 million in Q4 '24 and $236.2 million in calendar year '25 compared to $160.2 million in calendar year '24. These increases were driven by sales of Vafseo and an increase in Auryxia sales.\"</li>\n<li>Ostrowski also noted, \"Net loss in Q4 '25 decreased to $12.2 million as compared to a net loss of $22.8 million in Q4 '24. Net loss for the year also decreased to $5.3 million in calendar year '25 as compared to a net loss of $69.4 million in calendar year '24.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Management did not provide explicit revenue guidance for 2026, but Butler indicated, \"we're not guiding for revenue...we absolutely expect and are seeing growth from that level. We don't know exactly how quickly that will increase.\"</li>\n<li>Butler described expectations for Vafseo growth as \"steady growth month-over-month, quarter-over-quarter as we start to penetrate deeper in terms of breadth and depth.\"</li>\n<li>The company plans to initiate a Phase II open-label basket trial for AKB-097 in the second half of 2026 and a Phase I study in healthy volunteers of AKB-9090 in the first half of 2026.</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Total revenues for Q4 2025 were $57.6 million, with Vafseo net product revenues at $6.2 million and Auryxia net product revenues at $48.1 million. Net loss in Q4 2025 was $12.2 million. Cash and cash equivalents as of year-end stood at $184.8 million.</li>\n<li>Ostrowski indicated, \"We believe our existing cash resources and cash from operations will be sufficient to fund our current operating plans for at least the next 2 years.\"</li>\n<li>Cost of goods sold was $12.5 million in Q4 2025. R&amp;D expenses rose to $26.6 million, including a $12.8 million charge related to AKB-097 acquisition. SG&amp;A expenses were $26.1 million.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Julian Harrison, BTIG: Asked about expectations for Vafseo growth in 2026 and inventory-adjusted demand. Butler responded, \"we're not guiding for revenue...demand basically has been flat. We had $12 million in the third quarter, $11 million in the fourth quarter...we absolutely expect and are seeing growth from that level.\"</li>\n<li>Harrison also questioned the impact of upcoming VOICE study data. Butler stated, \"as these things are published available and our sales and medical affairs folks can use them, these are the things that influence utilization and physicians.\"</li>\n<li>Unknown Analyst (Jefferies): Inquired about refill rates and anemia manager education. Grund explained, \"We've seen this continuation of this high 80%, 90% adherence rate even through the second prescription.\"</li>\n<li>Unknown Analyst (Leerink Partners): Asked about the VOCAL study endpoints and protocol changes for AKB-097. Burke said, \"The primary endpoint is non-inferiority for hemoglobin control...the red blood cell study will be interesting and important.\"</li>\n<li>Unknown Analyst (Piper Sandler): Queried about the upcoming R&amp;D Day. Butler stated, \"we really want to focus on praliciguat and 097...hearing the excitement around that product from people other than Akebia employees, I think, is important.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts were focused on operational execution, adherence improvements, and clinical data catalysts, with a neutral-to-slightly-positive tone as they sought further clarity but acknowledged progress.</li>\n<li>Management maintained a confident and proactive tone, with Butler saying, \"I've never been more confident that the data that we're generating supports that managing anemia with a HIF-PHI...is going to be standard of care.\"</li>\n<li>Compared to the previous quarter, management’s tone shifted from addressing operational hurdles to emphasizing growth potential and confidence in clinical differentiation and pipeline expansion.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Management’s commentary moved from operational challenges and protocol implementation in Q3 2025 to broader prescriber access and improved adherence in Q4 2025.</li>\n<li>The rare kidney disease pipeline was introduced as a new strategic focus, with multiple mid-stage and early-stage assets detailed for the first time.</li>\n<li>Q4 highlighted a decrease in Vafseo revenue due to inventory drawdown, but stronger cash and decreased net loss were reported.</li>\n<li>Analysts in Q4 focused more on growth prospects, data catalysts, and pipeline differentiation compared to operational issues and initial launch metrics in Q3.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management cautioned about generic competition for Auryxia, stating, \"expect Auryxia revenues to decrease in 2026 as compared to 2025 Auryxia revenues.\"</li>\n<li>Adherence and operational execution for Vafseo remain under close watch, with ongoing efforts to improve protocols and education.</li>\n<li>No explicit mention of regulatory risks or additional financial uncertainties beyond those discussed.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Akebia management remains confident in the commercial trajectory of Vafseo and the strategic expansion into rare kidney disease therapies, highlighting improved adherence, expanded prescriber access, and a robust pipeline. With upcoming data from VOCAL and VOICE studies, anticipated protocol-driven growth, and a strong balance sheet, the company is positioned to pursue standard-of-care status for Vafseo in the $1 billion U.S. dialysis market while advancing multiple clinical programs in 2026 and beyond.</p>\n<p><a href=\"https://seekingalpha.com/symbol/akba/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557945-akebia-outlines-2026-pipeline-expansion-and-expects-vafseo-data-catalysts-in-1b-dialysis",
            "pub_date": "2026-02-27 00:31:30",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557936",
            "title": "PayPal drops on report Stripe isn't in talks for a takeover",
            "description": "<html><body><p data-eci=\"true\">PayPal (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a></span>) fell 2.6% after a report that the company isn't in talks to sell itself to Stripe (Stripe) or anyone else. </p>\n<p>PayPal (<a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a>) has been working for months to prepare for a possible activist campaign or unwanted takeover offer, according to a<a href=\"https://www.semafor.com/article/02/26/2026/paypal-stripe-not-currently-in-talks\" rel=\"nofollow\" target=\"_blank\" title=\" Semafor report \"> Semafor report </a>on Thursday, which cited people familiar with the matter. </p>\n<p>PayPal (<a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a>) declined to comment to Semafor. Stripe didn’t immediately return a request for comment. </p>\n<p>The Semafor item comes after a Bloomberg report on Tuesday that <span>Stripe was<a href=\"https://seekingalpha.com/news/4556161-paypal-jumps-on-report-stripe-is-considering-acquisition\" target=\"_blank\" title=\" considering an acquisition \"> considering an acquisition </a>of all or parts of PayPal (<a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a>). PayPal shares soared 6% on Monday after a Bloomberg report that PayPal<span> had piqued the interest of<a href=\"https://seekingalpha.com/news/4555316-paypal-stock-jumps-after-stock-slump-said-to-spark-suitors-interest#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews\" rel=\"noopener\" target=\"_blank\" title=\" some potential acquirers. \"> some potential acquirers.</a></span></span></p>\n<p> </p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557936-paypal-drops-on-report-stripe-isnt-in-talks-for-a-takeover",
            "pub_date": "2026-02-27 00:31:30",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557942",
            "title": "Hormel expects 1%–4% organic net sales growth in 2026 as it divests whole-bird turkey business and advances protein strategy",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: Hormel Foods Corporation (HRL) Q1 2026</p>\n<h3>Management View</h3>\n<ul>\n<li>Interim CEO Jeffrey Ettinger announced \"organic net sales growth of 2%, which marks our fifth consecutive quarter of organic net sales growth. We also achieved adjusted diluted earnings per share of $0.34.\" Ettinger emphasized the \"strength of our protein-centric portfolio\" and highlighted \"high single-digit organic net sales growth\" in both Foodservice and International segments, noting that this was \"partially offset by the decline in our Retail segment.\"</li>\n<li>Ettinger outlined the \"definitive agreement to sell our whole-bird turkey business to Life-Science Innovations,\" clarifying, \"the sale involves the hen side of our turkey complex\" but \"will not affect our value-added turkey products, and we will continue to own and use the Jennie-O brand name.\" The transaction is expected to close by the end of fiscal Q2 and is designed to \"reduce our exposure to volatile commodity-driven businesses and sharpen our focus on our value-added protein portfolio.\"</li>\n<li>President John Ghingo stated, \"We had an encouraging start to fiscal 2026 with strong performance in both our Foodservice and International segments.\" He pointed to \"strategic exit from select non-core private label snack nuts items\" as a factor in Retail's decline but highlighted that \"priority brands delivered year-over-year dollar sales consumption growth, including Jennie-O ground turkey, Planters snack nuts, Hormel Gatherings party trays, Applegate meats, and Hormel entrées.\"</li>\n<li>Ghingo introduced several leadership changes, including the appointment of Jeff Baker as Group Vice President of Enterprise Business Performance, Natosha Walsh as Group Vice President of Retail Sales, Jason Levine as Enterprise Chief Marketing Officer, and Domenic Borrelli as Executive Vice President of Retail.</li>\n<li>Interim CFO Paul Kuehneman reported, \"Q1 net sales were just over $3 billion, a 2% organic net sales increase compared to the prior year... Adjusted operating income for the first quarter was $247 million, and adjusted operating margin was 8.2%.\" Kuehneman confirmed \"cash flow from operations was $349 million, up $26 million from last quarter.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Kuehneman reaffirmed, \"we are reiterating our adjusted full year fiscal 2026 guidance. We continue to expect organic net sales growth of 1% to 4%... adjusted operating income growth of 4% to 10%, and adjusted diluted earnings per share to be in the range of $1.43 to $1.51 per share.\"</li>\n<li>Ettinger stated, \"For Q2, we expect to deliver another quarter of top line growth and adjusted diluted EPS that is in the range of flat to slightly up compared to last year.\"</li>\n<li>The impact of the pending whole-bird turkey transaction on fiscal 2026 is expected to be a reduction of approximately $50 million to net sales, with the majority of sales remaining part of reported results for the year.</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Kuehneman reported, \"Gross profit continued to be hampered in the first quarter with top line growth more than offset by higher input costs and higher-than-expected logistics expenses.\"</li>\n<li>Adjusted SG&amp;A as a percent of net sales was comparable to the prior year, with \"reduction in marketing and advertising expenses... offset by higher employee-related and legal expenses.\"</li>\n<li>Capital expenditures for the quarter were $69 million, with largest projects in China and continued investments in data and technology.</li>\n<li>Dividends returned approximately $160 million to stockholders, marking the 390th consecutive quarterly dividend.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Thomas Palmer, JPMorgan: Asked for Q2 segment-level expectations and for commentary on logistics headwinds. Ettinger explained, \"we believe we remain on a path to generate the sequential but modest bottom line improvement in Q2... we are carefully watching the more challenging freight cost environment.\"</li>\n<li>Palmer also questioned the rationale for the whole turkey divestiture. Ettinger said, \"it's highly volatile and it's low margin... in a typical year, it is significantly dilutive to retail margins,\" while Ghingo described the move as allowing \"us to increase our focus and accelerate the efforts on that part of the business, in particular, from a Retail perspective or thriving ground turkey business.\"</li>\n<li>Leah Jordan, Goldman Sachs: Sought more detail on the Retail segment and future margin improvement. Ghingo detailed that \"profitability for the quarter, certainly below prior year\" due to commodity costs and logistics, but stated, \"we will continue to get additional benefits from that second wave of pricing action in Q2 and beyond.\"</li>\n<li>Ryan Edward Lavin, Barclays: Asked about Foodservice pricing. Ghingo responded, \"there is a lag time on our Foodservice. The prices will follow the markets... pricing coming back in line with the market movements, which did help us on the margin side.\"</li>\n<li>Heather Jones, Heather Jones Research: Queried the volume decline in Retail. Ghingo attributed it to \"the exit of that private label snack nuts business,\" \"volume softness on a couple of businesses, including SKIPPY,\" and \"elasticities related to pricing.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts focused on segment-level expectations, margin improvement, and the strategic rationale behind the whole-bird turkey sale, often pressing for details about headwinds and profit recovery, exhibiting a neutral to slightly skeptical tone.</li>\n<li>Management maintained a confident tone in prepared remarks, highlighting \"conviction as we look ahead\" and \"confidence in the plan we are executing,\" but became more cautious when discussing logistics costs and Retail profitability, using language such as \"carefully watching\" and \"committed to executing with urgency and precision.\"</li>\n<li>Compared to the previous quarter, management's tone shifted from addressing disappointment and missed earnings goals to signaling a more optimistic stance based on early 2026 results.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Guidance for fiscal 2026 was reiterated, with organic net sales growth of 1% to 4% and adjusted diluted EPS of $1.43 to $1.51 per share, unchanged from Q4 2025.</li>\n<li>The strategic focus sharpened with the announcement of the whole-bird turkey divestiture, compared with continued portfolio reshaping and transformation initiatives discussed previously.</li>\n<li>Analyst questions this quarter centered more on the operational impacts and rationale behind strategic divestitures, as well as logistics and margin recovery, while the previous quarter featured more inquiries about cost assumptions and portfolio review.</li>\n<li>Management appeared more confident in growth levers and strategic direction, compared to the defensive posture adopted in Q4 2025 following a disappointing fiscal year.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management flagged higher input costs—especially beef, pork trim, and nuts—as ongoing headwinds, noting \"beef remained a significant inflationary pressure\" and \"pork trim increased 12% compared to last year.\"</li>\n<li>Unexpected increases in logistics and transportation expenses in Q1 were highlighted as an emerging concern, with monitoring underway for persistence.</li>\n<li>The divestiture of the whole-bird turkey business is expected to reduce sales by approximately $50 million in fiscal 2026, with a larger impact in 2027.</li>\n<li>Analysts questioned the ability to achieve margin improvement in Retail and the sustainability of profit recovery given commodity and logistics pressures.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Management emphasized that Hormel Foods began fiscal 2026 with momentum in both Foodservice and International segments, supported by its protein-centric strategy and a more focused brand portfolio. The company reaffirmed its full-year guidance for organic net sales and earnings, citing benefits from pricing actions, operational improvements, and the upcoming divestiture of the volatile whole-bird turkey business. While input and logistics costs remain challenges, leadership changes and targeted investments are positioned as key drivers for long-term growth and margin expansion.</p>\n<p><a href=\"https://seekingalpha.com/symbol/hrl/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557942-hormel-expects-1-percent-4-percent-organic-net-sales-growth-in-2026-as-it-divests-whole-bird",
            "pub_date": "2026-02-27 00:20:47",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557941",
            "title": "NovoCure outlines $675M–$705M 2026 revenue target as new indications fuel growth",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: NovoCure Limited (NVCR) Q4 2025  </p>\n<h3>Management View</h3>\n<ul>\n<li>Executive Chairman William Doyle highlighted that \"2025 was a year of progress and change at NovoCure. We generated a record $655 million in net revenues last year, an 8% increase from 2024.\" Doyle pointed to final data presentations from two large randomized trials, FDA PMA submissions for TTFields therapy in pancreatic cancer and brain metastases, and the rollout of product enhancements for TTFields therapy. </li>\n<li>Doyle announced the first milestone of 2026 was the FDA approval of Optune Pax for locally advanced pancreatic cancer, with regulatory filings submitted in Europe and Japan. He further stated, \"We expect Optune Pax to be a significant contributor to our long-term growth and are eager to begin treating patients in the coming weeks.\"</li>\n<li>Doyle provided a management update: \"Dr. Nicolas Leupin, our Chief Medical Officer, resigned from the company effective February 25...Dr. Uri Weinberg, our Chief Innovation Officer, will now also assume the role of Chief Medical Officer.\" </li>\n<li>CEO Frank Leonard reported, \"2025 was our most successful commercial year to date,\" citing substantial active patient growth across major markets: \"10% year-over-year growth in Germany, 19% in France, and 29% in Japan.\" He noted U.S. active patient growth was 4% after being flat in recent years. Leonard also described plans for a \"tailwind from new market launches in Spain, Czechia, and British Columbia,\" with expectations for modest first-year revenue contributions.</li>\n<li>Leonard explained the Optune Lua launch in Japan is proceeding, and that the company has \"rightsized our marketing spend based on the current demand and are prioritizing investments in indications with a higher return potential, such as pancreatic cancer.\" He emphasized the rapid FDA review and approval of Optune Pax, stating, \"the FDA review was completed exactly at the 180-day mark, with approval received on February 11.\"</li>\n<li>CFO Christoph Brackmann stated, \"Fourth quarter net revenue was $174 million, and full year net revenue totaled $655 million, representing 8% year-over-year growth for both periods.\" Brackmann reported, \"We recognized $3.5 million from Optune Lua claims in the quarter, including $2.4 million from non-small cell lung cancer.\" He addressed a recent Medicare billing issue, saying, \"we do not expect any negative impact on revenue recognition from this matter.\"</li>\n<li>Brackmann provided 2026 guidance: \"annual net revenue guidance at constant exchange rates of $675 million to $705 million, representing year-over-year growth between 3% and 8%.\" He also noted, \"we have decided not to go beyond the $200 million already drawn from our current credit facility.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Management issued guidance of $675 million to $705 million in net revenue for 2026, assuming Optune Gio net revenue growth in the low to mid-single digits and $15 million to $25 million in net revenue contributions from non-GBM products. Brackmann stated, \"For 2026, we expect gross margin in the mid-70s percentage range.\"</li>\n<li>Adjusted EBITDA guidance for 2026 was set at negative $20 million to breakeven for the full year. Leonard emphasized, \"we want to drive to adjusted EBITDA breakeven as a possibility this year.\"</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Fourth quarter net revenue was $174 million, with full year net revenue of $655 million, both up 8% year-over-year. Gross margin was 76% for the quarter and 75% for the full year, compared to 79% and 77% in the respective 2024 periods. </li>\n<li>R&amp;D costs in the quarter were $61 million, up 19% year-over-year, and $225 million for the full year. Sales and marketing expenses were $69 million for Q4 and $240 million for the year. G&amp;A expenses for Q4 were $43 million, down 41% year-over-year; full year G&amp;A was $178 million, down 6%. </li>\n<li>Net loss for Q4 was $24 million, loss per share was $0.22; full-year net loss was $136 million or $1.22 per share. Adjusted EBITDA was negative $16 million for Q4 and negative $34 million for the full year. Cash and investments ended at $448 million after repayment of $561 million in convertible notes.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Jason Bednar, Piper Sandler: Asked about the rationale for providing guidance and details behind revenue assumptions, including new international markets and denied claims. Leonard explained, \"one of the core messages that we've heard is that we need to speak more clearly in terms of setting expectations of what we can accomplish in the coming year.\" Brackmann added, \"there's our GBM business in established markets...GBM in newer markets...and then the third bucket of growth would be new indications...expecting contributions in the range of $15 million to $25 million.\"</li>\n<li>Kevin Joaquin, Evercore ISI: Inquired if guidance for Optune Gio reflected market conservatism. Leonard responded, \"we are not seeing -- we're not signaling a conservatism or a moderation. We're trying to signal that...there are still many patients who will benefit from Optune Gio.\"</li>\n<li>Larry Biegelsen, Wells Fargo: Asked how Optune Pax will be prescribed and lessons learned from lung launch. Leonard highlighted, \"Optune Pax is being approved for locally advanced pancreatic cancer in a first-line setting...a highly motivated patient population.\"</li>\n<li>Albert Aginis, Leerink Partners: Asked about sales force allocation for Optune Pax. Doyle answered, \"we have an established team that we've trained over the last 2 years...we are simply leveraging the team that we have.\"</li>\n<li>Emily Bodnar, H.C. Wainwright: Requested details on revenue contribution for Optune Pax and sales force coverage. Leonard explained, \"as we launch in a new indication, we do...need to go through a process of working with the payers to establish coverage policies,\" and Brackmann noted, \"we expect it will take us about 1 to 2 years to get coverage on a more routine basis for commercial payers.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts largely focused on clarity of guidance, revenue contributions from new markets, and execution around new product launches, with a neutral to slightly positive tone as reflected in congratulatory remarks and requests for detail.</li>\n<li>Management response was confident and direct, with Leonard stating, \"we want to send the signal first at the top line that we are committed to returning the company to steady growth,\" while Brackmann outlined specifics around guidance and expense management. </li>\n<li>Compared to the previous quarter, the sentiment moved from cautious optimism about new launches to a more assertive and confident stance on guidance, profitability timelines, and operational execution.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Management shifted from emphasizing the challenges and learning curve of new launches (notably in lung cancer) to highlighting a record year, a catalyst-rich 2026, and the issuance of annual revenue and profitability guidance for the first time.</li>\n<li>Strategic focus evolved from building infrastructure for multi-indication launches to leveraging existing teams and platforms for new product rollouts.</li>\n<li>Analysts’ questions shifted from launch execution details and ramp expectations to specifics on revenue guidance, market assumptions, and profitability.</li>\n<li>Key metrics improved, with net revenue and active patient counts reaching record highs, and management now targeting breakeven adjusted EBITDA as early as 2026, compared to a previous target of 2027.</li>\n<li>Management confidence increased, with explicit statements about readiness to guide and a clear path to profitability.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Doyle addressed a management change, noting the resignation of Chief Medical Officer Dr. Nicolas Leupin and the appointment of Dr. Uri Weinberg to the combined CMO/Chief Innovation Officer role.</li>\n<li>Brackmann discussed a recent Medicare billing suspension, noting that billing privileges were reinstated retroactively and that \"we do not expect any negative impact on revenue recognition from this matter.\"</li>\n<li>Leonard cautioned that in new indication launches, \"there will be a lag as we establish the coverage policies and the payment policies with payers in the United States,\" suggesting a delay in revenue recognition for Optune Pax.</li>\n<li>Brackmann noted that some launch costs and gross margin pressures are expected as new indications come online and coverage is established.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>NovoCure’s 2025 performance marked a year of record net revenue and active patient growth, underpinned by expansion in key markets and regulatory milestones including the FDA approval of Optune Pax for pancreatic cancer. The company signaled a clear path toward profitability with 2026 guidance of $675 million to $705 million in net revenue and a target of breakeven adjusted EBITDA, leveraging existing sales infrastructure for new product launches and focusing on operational discipline. Management changes and recent Medicare billing challenges were addressed transparently, with no expected negative impact on revenue. The upcoming year is described as catalyst-rich, with expectations for further regulatory, clinical, and commercial milestones to drive long-term growth.</p>\n<p><a href=\"https://seekingalpha.com/symbol/nvcr/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557941-novocure-outlines-675m-705m-2026-revenue-target-as-new-indications-fuel-growth",
            "pub_date": "2026-02-27 00:20:47",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557928",
            "title": "Beyond Meat has a vibrant protein drink lineup",
            "description": "<html><body><p data-eci=\"true\">Beyond Meat (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/BYND\" title=\"Beyond Meat, Inc.\">BYND</a></span>) continues to expand its product lineup into beverages. The company announced the launch of four new flavor variations of its Beyond Immerse sparkling protein drink that combines plant protein, fiber, antioxidants, and electrolytes. </p>\n<p>The company started selling the Beyond Immerse line in January when it became available for a limited time via the direct-to-consumer site, Beyond Test Kitchen. Building on that early momentum, the brand is adding Cherry Berry, Strawberry Lemonade, Piña Colada, and Cucumber Grapefruit versions of the protein drink for a limited time through Beyond Test Kitchen.</p>\n<p>\"Beyond Immerse represents a meaningful next chapter for our brand as we expand beyond center-of-the-plate protein,\" highlighted CEO Ethan Brown. \"We challenged ourselves to redefine the protein drink, designing a beverage that immerses the body not only in protein but more broadly in the remarkable power of plants,\" he added.</p>\n<p>The protein drinks are available in 10g and 20g varieties and are packed with 7g of fiber, antioxidants, and electrolytes.</p>\n<p>Shares of Beyond Meat (<a href=\"https://seekingalpha.com/symbol/BYND\" title=\"Beyond Meat, Inc.\">BYND</a>) were down 3.3% in late morning trading. The market cap for the stock is down to about $360M. Short interest stands at 31.1% of the total float.</p>\n<p> </p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557928-beyond-meat-has-a-vibrant-protein-drink-lineup",
            "pub_date": "2026-02-27 00:15:54",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557934",
            "title": "Celsius targets gross margin return to low 50% by end of 2026 as integration and innovation drive portfolio expansion",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: Celsius Holdings, Inc. (CELH) Q4 2025</p>\n<h3>Management View</h3>\n<ul>\n<li>John Fieldly, CEO, opened by highlighting that \"We continue to execute with momentum and operating discipline, and we are reinforcing the scale of our platform as we build a modern energy portfolio.\" He announced a full year record revenue of $2.5 billion and emphasized the disciplined approach to growth and scale, with a focus on consumer proximity and execution alongside Pepsi and retail partners.</li>\n<li>Fieldly stated the portfolio, including CELSIUS, Alani Nu, and Rockstar Energy, now represents approximately 1/5 of the U.S. energy market in tracked channels for the full year, and contains two billion-dollar brands. He outlined strategic efforts to broaden reach, stating integration of Alani Nu into the PepsiCo system is substantially complete, with full completion expected by the end of Q1 2026, and Rockstar integration targeted for the first half of 2026.</li>\n<li>Fieldly highlighted innovation such as the national launch of the Fizz-Free line and a more intentional cadence of limited time offers (LTOs) to expand reach and trial. International expansion is a long-term growth lever, now present in about 10 markets, with a new President of International, Garrett Quigley, brought on to scale global operations.</li>\n<li>On marketing, Fieldly introduced a new in-house brand studio to unify and accelerate brand storytelling and activation across the portfolio. He reiterated the focus on zero sugar, functional energy, and operational discipline to maintain relevance and drive sustainable growth.</li>\n<li>Jarrod Langhans, CFO, provided context on the accounting treatment for Rockstar during integration, with $45 million recorded in net sales and an additional $6 million in other income for the quarter. \"As we move into the first quarter, we expect to fully transition the U.S. portion of the business to the finished goods model and we expect that only the Canadian portion will remain in the other income.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Fieldly stated, \"We have a clear strategy and priorities for 2026 and believe they will support sustainable, profitable growth.\" Langhans indicated that as integrations progress, \"we expect margins to expand across 2026 and return to a more normalized profile, with gross margins in the low 50s driven by savings across raw materials, scrap, manufacturing tolling fees, freight and package and brand mix, offset in part by tariffs and aluminum costs.\"</li>\n<li>Management expects the Alani integration to be completed by the end of Q1 2026 and Rockstar by the first half of 2026, projecting that integration and operational efficiencies will support margin expansion.</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Consolidated Q4 revenue was approximately $722 million, with full year consolidated revenue at $2.5 billion. Alani Nu achieved record net sales of $370 million in Q4, contributing $1 billion since acquisition. Brand CELSIUS delivered $1.46 billion in net sales for the year, growing 7.5% year-over-year.</li>\n<li>Gross profit for Q4 was $341.8 million, with a margin of 47.4%, impacted by dilution from Rockstar and integration costs. Full year gross profit margin was 50.4%.</li>\n<li>GAAP net income for the quarter was $24.7 million and adjusted EBITDA was $134.1 million. Operating cash flow was $359 million for the year, with $399 million in cash and $670 million in total debt at year end. The company reduced debt by $200 million and repurchased $40 million in shares during Q4, with $260 million remaining under the repurchase program.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Filippo Falorni, Citigroup, asked about spring shelf space resets and the timing of benefits. CEO Fieldly responded, \"We do expect those to continue to materialize through the end of spring, really with the biggest gains, especially for Alani, would be in convenience.\"</li>\n<li>Peter Grom, UBS, inquired about the $25 million net benefit from CELSIUS vs. Alani and inventory levels. CFO Langhans said, \"We're committed to really tightening up those peaks and valleys...as a portfolio, playing a much more scaled business, we'll be able to get those a bit tighter and manage that.\"</li>\n<li>Bonnie Herzog, Goldman Sachs, questioned gross margin trajectory and Midwest premium impact. Langhans replied, \"Our target for this year is to get back to a more normalized low 50s...Alani will be fully integrated by end of Q1 and Rockstar by the end of Q2.\"</li>\n<li>Andrea Teixeira, JPMorgan, addressed SKU prioritization and margin predictability. Fieldly emphasized, \"Velocity is very important in the category. That's what is going to continue to drive it.\"</li>\n<li>Kevin Grundy, BNP Paribas, focused on distribution gains, shelf space sources, and velocity. Fieldly noted, \"There is a lot more space coming in the energy category as it's becoming part of a daily lifestyle, daily routine.\"</li>\n<li>Gerald Pascarelli, Needham, asked about inventory benefits and shelf space growth for Alani. Langhans explained, \"I would definitely see that as more of an opportunistic move as opposed to a pull back or pull forward.\" Fieldly described Alani's expansion as driven by category growth and evolving consumer dynamics.</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts' tone was inquisitive and slightly pressing, focused on inventory timing, margin recovery, and the sustainability of velocity and shelf space gains.</li>\n<li>Management delivered confident, disciplined responses, frequently referencing operational rigor and tight alignment with retail partners. Fieldly stated, \"We feel confident with the innovation. We're going to see the space gains.\"</li>\n<li>Compared to the previous quarter, management’s tone remained optimistic but provided more detail on integration milestones and operational discipline, while analysts pressed for greater clarity on timing and risk factors.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>This quarter saw explicit updates on integration progress and margin recovery plans, compared to last quarter’s focus on the initial impact of acquisitions and distribution expansion.</li>\n<li>Management shifted from discussing the mechanics of integration to providing concrete timelines and targets, such as gross margin returning to the low 50% range by the end of 2026.</li>\n<li>Analysts continued to probe inventory movements and margin sustainability, but questions became more focused on the operational cadence and risk of volatility as integrations near completion.</li>\n<li>Key metrics such as consolidated revenue, gross margins, and inventory-related timing effects were expanded upon in detail this quarter relative to Q3.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Integration and distribution transition costs impacted gross margin, with ongoing volatility possible as integrations complete.</li>\n<li>Management cited tariffs and aluminum costs as ongoing headwinds, while emphasizing mitigation through operational efficiencies and scale.</li>\n<li>Analysts consistently raised concerns about volatility in inventory management, timing of shelf resets, and the pace of margin normalization.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Celsius Holdings management underscored that 2025 was a year of record revenue and major portfolio scale as the company integrated Alani Nu and Rockstar, with the focus now on completing integrations, expanding shelf space, and driving operational discipline. The company projects gross margin to return to the low 50% range by the end of 2026, supported by integration synergies, supply chain improvements, and ongoing innovation, while continuing to prioritize brand growth and long-term value creation.</p>\n<p><a href=\"https://seekingalpha.com/symbol/celh/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557934-celsius-targets-gross-margin-return-to-low-50-percent-by-end-of-2026-as-integration-and",
            "pub_date": "2026-02-27 00:10:47",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557935",
            "title": "Climb Global Solutions targets $250M in Fortinet gross billings within 18 months as M&A strategy accelerates",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: Climb Global Solutions (CLMB) Q4 2025</p>\n<h3>Management View</h3>\n<ul>\n<li>CEO Dale Foster described 2025 as \"another exceptional year for Climb as we generated record results across all key financial metrics.\" Foster highlighted the company's selective vendor onboarding, stating, \"In the fourth quarter alone, we evaluated nearly 100 potential vendor relationships and signed agreements with only 2 of them.\" </li>\n<li>Foster announced a new partnership with Fortinet, calling it \"quickly becoming a primary onboarding focus\" and expected to become a \"meaningful contributor\" to the business. He also detailed the ongoing relationship with Darktrace, noting, \"In Q4, Climb had 70 partners transact over $13 million in Darktrace product offerings.\"</li>\n<li>Foster revealed the acquisition of interworks.cloud, a Greece-based specialist cloud distributor, stating it \"enhance[s] our ability to drive cross-sell opportunities, deepen our engagement with our vendors and reseller partners and further position Climb as a distributor of choice across the Southeastern Europe region.\"</li>\n<li>Foster explained the strategic rationale: \"We expect the transaction to be immediately accretive to our earnings and adjusted EBITDA and look forward to unlocking synergies and cross-selling opportunities.\"</li>\n<li>CFO Matthew Sullivan reported, \"Gross billings increased 3% to $625.4 million compared to $605 million in the year ago quarter... Net sales in the fourth quarter of 2025 increased 20% to $193.8 million compared to $161.8 million, which primarily reflects organic growth from new and existing vendors.\" He added, \"Net income in the fourth quarter of 2025 remained flat at $7 million or $1.52 per diluted share compared to the prior year period.\"</li>\n<li>Sullivan announced, \"The Board has determined to suspend our quarterly cash dividend beginning in the first quarter of 2026. This decision allows us to retain additional capital to support organic growth initiatives and strategic acquisitions while further strengthening our financial flexibility.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Foster emphasized, \"Looking ahead, we remain focused on accelerating organic growth... We will also continue to pursue accretive M&amp;A opportunities that can strengthen our vendor portfolio and expand our geographic footprint.\"</li>\n<li>Sullivan stated, \"With a disciplined approach to expansion and a continued focus on execution, we believe we are well positioned to deliver another year of growth and enhance profitability in 2026.\"</li>\n<li>Management expects the interworks.cloud acquisition to be \"immediately accretive to our earnings and adjusted EBITDA.\"</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Sullivan stated, \"Gross billings increased 3% to $625.4 million... Net sales... increased 20% to $193.8 million... Gross profit in the fourth quarter was $29.8 million compared to $31.2 million.\"</li>\n<li>SG&amp;A expenses were $18.2 million, with SG&amp;A as a percentage of gross billings at 2.9%.</li>\n<li>Adjusted net income was $7 million or $1.53 per diluted share versus $10.3 million or $2.26 per share for the prior year.</li>\n<li>Adjusted EBITDA was $13 million compared to $16.1 million for the same period in 2024. Effective margin was 43.6% versus 51.5% last year.</li>\n<li>Cash and cash equivalents totaled $36.6 million, with working capital increasing by $27.7 million. Outstanding debt was $200,000 with no borrowings under the $50 million credit facility.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Keith Housum, Northcoast Research, asked about year-over-year performance without last year's large transaction. Sullivan replied, \"Our recurring and organic growth still was in the high teens for Q4 compared to Q4 of last year.\"</li>\n<li>Housum inquired about the impact of the Citrix departure. Foster responded, \"We looked at it as a $50 million to $60 million hole... our team still with that big hole, grew at 3%.\"</li>\n<li>Housum questioned Interworks' EBITDA run rate. Foster said, \"That's a good starting point for them... Microsoft... set a threshold. So there was a lot of scrambling... we get to that $30 million threshold with Microsoft.\"</li>\n<li>Vincent Colicchio, Barrington Research, asked about broad-based growth and lumpy deals. Foster replied, \"No lumpy deals in the quarter like we had before 2024 and Q4, but it was across our vendors.\" On AI, Foster indicated the company is identifying internal use cases and driving efficiency with its CIO.</li>\n<li>William Dezellem, Tieton Capital Management, pressed for Fortinet relationship scale. Foster said, \"It's about a $2.5 billion addressable market in the U.S... 10% of that is something that we're going after in the next 18 months, and we think we can get there. And I think Fortinet will be our top 3 vendor this time next year.\"</li>\n<li>Howard Root, private investor, questioned M&amp;A strategy and dividend suspension. Foster confirmed, \"The dividend will be going toward the M&amp;A side of things... I have... been in Western Europe more than I have been before because there's that many targets.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts focused on acquisition synergies, organic growth, vendor transitions, and profitability, showing constructive yet probing interest. The tone remained neutral to slightly positive, with congratulations on results and detailed questions on execution.</li>\n<li>Management's remarks were confident and strategic, using phrases like \"We expect the transaction to be immediately accretive\" and \"We are well positioned to deliver another year of growth.\" During Q&amp;A, Foster remained candid yet optimistic, especially regarding M&amp;A and operational efficiency.</li>\n<li>Relative to the previous quarter, both management and analyst tone remain consistent, though the current quarter saw more emphasis on growth opportunities via M&amp;A and vendor partnerships.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Guidance language shifted to a stronger emphasis on M&amp;A acceleration and capital reallocation, with the dividend suspension marking a notable change from prior quarters.</li>\n<li>Strategic focus has intensified on vendor curation, onboarding larger partners like Fortinet, and expanding geographic reach through acquisitions such as interworks.cloud.</li>\n<li>Key financial metrics show continued growth in billings and sales, while profitability measures, such as adjusted EBITDA and effective margin, declined due to the absence of large prior-year transactions.</li>\n<li>Analysts maintained focus on organic growth, partner transitions, and the scale of new deals, with recurring questions about the durability of partnerships, vendor mix, and acquisition strategy.</li>\n<li>Management’s confidence in operational improvements and efficiency measures has increased, with multiple references to leveraging AI and internal development for process acceleration.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management identified the risk of AI disruption in the market but expressed confidence in adapting quickly, stating, \"We are still connecting technology builders with users. We can pivot quickly, as we have done over these last 8 years.\"</li>\n<li>The departure of Citrix posed a revenue gap, but Foster emphasized successful vendor replacement and growth.</li>\n<li>Working capital fluctuations were attributed to timing of collections and payables, with management expecting normalization.</li>\n<li>Analyst concerns centered on sustained profitability, integration of acquisitions, and the scalability of new partnerships.</li>\n<li>The decision to suspend the dividend introduces execution risk regarding capital deployment and the pace of M&amp;A.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Climb Global Solutions' management highlighted a year of strong organic growth, strategic vendor partnerships, and a transformative acquisition in interworks.cloud. The company is reallocating capital from dividends to accelerate M&amp;A and fuel expansion, with a clear target to capture $250 million in Fortinet-related gross billings within 18 months. Management remains confident in its adaptability, operational efficiency initiatives, and ability to replace lost vendor revenue, all while positioning Climb for continued growth and profitability in 2026.</p>\n<p><a href=\"https://seekingalpha.com/symbol/clmb/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557935-climb-global-solutions-targets-250m-in-fortinet-gross-billings-within-18-months-as-m-and-a",
            "pub_date": "2026-02-27 00:10:47",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557892",
            "title": "Stellantis shares rise despite EV write-off as turnaround hopes build",
            "description": "<html><body><p data-eci=\"true\">Despite suffering a sizable loss in 2026 tied to a €25B write-off on its electric vehicle business, shares of Stellantis (<span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/STLA\" title=\"Stellantis N.V.\">STLA</a></span></span>) are higher on Thursday amid expectations that the company will return to a profit under the direction of CEO Antonio Filosa.</p>\n<p>With the EV loss behind it, Stellantis (<a href=\"https://seekingalpha.com/symbol/STLA\" title=\"Stellantis N.V.\">STLA</a>) said it expects to “progressively” improve net revenue, adjusted operating income margin, and industrial free cash flow in 2026 and to see progressive improvements from the first half of the year to the second half.</p>\n<p>“In the second half of the year we began to see initial, positive signs of progress with the early results of our drive to improve quality, strong execution of the launches of our new product wave, and a return to top-line growth. In 2026 our focus will be on continuing to close the execution gaps of the past, adding further momentum to our return to profitable growth,” Filosa said in a statement.</p>\n<p>For FY25, however, the huge EV write-down drove Stellantis (<a href=\"https://seekingalpha.com/symbol/STLA\" title=\"Stellantis N.V.\">STLA</a>) to a loss of €22.3B ($26.3B) and an adjusted operating loss ((AOI)) of €842M with an AOI margin of negative 0.5%. This translated into a loss of €0.42 ($0.50) per share from a profit of €2.48 in 2024.</p>\n<p>The write-off was reflected in the second half, where Stellantis (<a href=\"https://seekingalpha.com/symbol/STLA\" title=\"Stellantis N.V.\">STLA</a>) incurred a loss of €0.60 per share from a profit of €0.08 in H2 2024.</p>\n<p>Sales improved, however, gaining 10% to €79.2B in the second half of 2025 from the same period last year, but were down 2% for all of 2025 to $153.5B.</p>\n<p>Shipments in the second half of 2025 reached 2.8M units, up 11% year-over-year, with North America showing the strongest improvement of +39% from a year ago.</p>\n<p>For the current year, Stellantis (<a href=\"https://seekingalpha.com/symbol/STLA\" title=\"Stellantis N.V.\">STLA</a>) expects to see a mid-single-digit percent increase in net revenue, a low-single-digit AOI margin (versus -0.5% in 2025)—albeit still pressured by a €1.6 tariff expense—and improved industrial free cash flow generation year-over-year (versus negative €4.65B in 2025).</p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557892-stellantis-shares-rise-despite-ev-write-off-as-turnaround-hopes-build",
            "pub_date": "2026-02-27 00:05:53",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        }
    ]
}